Reaction

Disinhibition reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,591 reports · 56 co-occurring drugs

As of the last recalculation, Disinhibition appears in 1,591 FAERS reports alongside 56 co-occurring drug terms. The strongest observed disproportionality signal is ASENAPINE MALEATE (PRR 251.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Asenapine Maleate151251.8256.2
Lithium Carbonate163139.8141.1
Valproate Sodium14097.197.7
Haloperidol15391.191.6
Haloperidol Lactate15389.489.9
Aripiprazole Oral19871.471.7
Aripiprazole Orally Disintegrating19871.471.7
Ziprasidone8163.363.6
Quetiapine Fumarate11253.353.5
Lithium7641.441.5
Lithium Bromatum7641.441.5
Olanzapine27139.639.7
Aripiprazole28036.136.2
Citalopram Hydrobromide21329.929.9
Fluoxetine13528.928.9
Fluoxetine Hydrochloride22626.826.9
Risperidone22525.625.7
Ziprasidone Mesylate2624.224.3
Citalopram21623.723.8
Clozapine19923.623.6
Quetiapine25720.620.7
Rasagiline Mesylate1315.415.4
Olanzapine Pamoate4615.115.1
Nicotine Polacrilex Mini1614.114.1
Nicotine Polarilex1614.114.1
Valproic Acid3314.014.0
Ethyl Alcohol2713.213.2
Oxazepam2012.312.3
Amantadine1311.111.1
Posaconazole Delayed-Release910.810.8
Alcohol3110.610.6
Isopropyl Alcohol2710.610.6
Tranexamic Acid710.310.3
Guanfacine610.010.0
Paroxetine Hydrochloride Hemihydrate2510.010.0
Paroxetine259.89.8
Diazepam Oral Solution (Concentrate)639.69.6
Diazepam Oral639.69.6
Paroxetine Hydrochloride649.59.6
Rifampicin79.19.1
Sumatriptan Succinate157.87.8
Posaconazole97.37.3
Dolutegravir Sodium57.37.3
Rotigotine87.37.3
Rivastigmine107.07.0
Derma Foam Excel Hand Sanitizer46.66.6
Ethanol46.56.5
Clobazam115.95.9
Fentanyl Citrate85.95.9
Memantine65.85.8
Memantine Hydrochloride65.85.8
Nicotine Polacrilex165.55.5
Nicotine165.25.2
Cannabidiol73.93.9
Brexpiprazole43.23.2
Esketamine Hydrochloride42.92.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.